Stryker Co. (NYSE:SYK) Stock Holdings Raised by Suncoast Equity Management

Suncoast Equity Management boosted its holdings in Stryker Co. (NYSE:SYK) by 1.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,886 shares of the medical technology company’s stock after acquiring an additional 1,267 shares during the quarter. Stryker accounts for approximately 4.8% of Suncoast Equity Management’s holdings, making the stock its 9th largest position. Suncoast Equity Management’s holdings in Stryker were worth $36,200,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in Stryker by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock worth $8,379,967,000 after buying an additional 143,631 shares in the last quarter. Morgan Stanley raised its holdings in shares of Stryker by 21.7% during the fourth quarter. Morgan Stanley now owns 5,978,782 shares of the medical technology company’s stock valued at $1,461,753,000 after purchasing an additional 1,066,751 shares during the last quarter. FMR LLC lifted its position in Stryker by 2.5% during the third quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock valued at $1,632,127,000 after purchasing an additional 144,208 shares during the period. Geode Capital Management LLC boosted its holdings in Stryker by 2.0% in the first quarter. Geode Capital Management LLC now owns 5,954,038 shares of the medical technology company’s stock worth $1,695,169,000 after purchasing an additional 117,786 shares during the last quarter. Finally, Northern Trust Corp grew its position in Stryker by 3.9% in the 3rd quarter. Northern Trust Corp now owns 3,505,595 shares of the medical technology company’s stock worth $957,974,000 after purchasing an additional 131,590 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Up 0.0 %

Shares of SYK stock traded up $0.06 on Tuesday, hitting $339.19. The stock had a trading volume of 607,175 shares, compared to its average volume of 1,246,103. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. The company has a market cap of $129.05 billion, a PE ratio of 41.14, a P/E/G ratio of 2.75 and a beta of 0.89. The business has a 50 day moving average price of $350.75 and a 200 day moving average price of $311.41. Stryker Co. has a one year low of $249.98 and a one year high of $361.41.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period in the previous year, the company posted $3.00 EPS. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. Research analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a dividend of $0.80 per share. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.94%. Stryker’s dividend payout ratio is currently 38.79%.

Analyst Ratings Changes

Several research firms have recently weighed in on SYK. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and increased their price target for the company from $315.00 to $360.00 in a report on Wednesday, January 31st. Roth Mkm raised their price objective on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Evercore ISI lifted their price target on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Finally, Wells Fargo & Company upped their price target on Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $339.22.

Insider Transactions at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Allan C. Golston sold 3,273 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock worth $72,845,768 over the last three months. 5.50% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.